실적분석 2026년 8월 27일

Materialise ($MTLS) Q2 2026 Earnings Analysis — Revenue Beats Estimates, Adjusted Operating Profit Guidance Raised

Earnings Scorecard

Revenue: $79.84 million (+8.1% year-over-year, vs. $68.50 million estimate) ✅ Beat

EPS: Diluted $0.07 (GAAP, USD-converted; €0.06 on a euro basis). The $0.04 estimate was on an adjusted basis and is not directly comparable

Guidance: Raised — Full-year 2026 adjusted operating profit of €12–14 million (previously €10–12 million); revenue guidance of €273–283 million maintained

Stock Reaction: +10.19% after-hours ($7.35) — as of 08-27 21:09 Korea time

What Went Well

Medical revenue +12.2%: Medical segment reached €36.87 million in Q2, leading company-wide growth

Adjusted operating profit +26.9%: Grew to €3.88 million, with margin expanding to 5.5%

Full-year profit guidance raised: Lifted adjusted operating profit guidance to €12–14 million

Manufacturing focused on medical and aerospace & defense pushed revenue higher, and cost discipline translated into improved profits. Share buybacks during the quarter and higher net cash also underscore the company's cash-generating ability.

What Fell Short

Software revenue declined: Q2 software revenue of €9.60 million, down 2.7% year-over-year

Gross margin contraction: Q2 gross margin came in at 56.8%, retreating from 58.3% a year earlier

Operating profit flat: GAAP operating profit of €2.785 million, roughly in line with a year ago

Despite the launch of new additive manufacturing collaboration products, software revenue declined, and a €689,000 impairment loss related to the eyewear business asset transfer was recorded as a one-time item. A large share of the net income surge reflects a base effect from improved financial income/expense compared with a sizable foreign-exchange loss a year earlier.

What Management Said

Management emphasized that double-digit growth in the medical segment, combined with a recovery in aerospace & defense-led manufacturing, drove the improvement in profitability. The full-year revenue target was maintained after absorbing the impact of non-core business divestitures, while the adjusted operating profit outlook was lifted on the basis of cost discipline and execution.

Market Reaction and What to Watch

The combination of medical growth, raised profit guidance, and stronger net cash prompted after-hours buying, analysts said.

Investors will look to confirm whether double-digit medical segment revenue growth continues into the second half.

Watch whether the adjusted EBITDA of the manufacturing segment returns to positive territory.

Gauge whether the high end of the full-year adjusted operating profit range (€14 million) is achievable.